This article has Open Peer Review reports available.
Tardive and spontaneous dyskinesia incidence in the general population
© Merrill et al.; licensee BioMed Central Ltd. 2013
Received: 5 December 2012
Accepted: 21 May 2013
Published: 28 May 2013
To identify the incidence rate of spontaneous dyskinesia (SD) and tardive dyskinesia (TD) in a general population and to examine the association between dykinesia and potential risk factors (exposure to metoclopramide [MCP], antipsychotic drugs, and history of diabetes and psychoses).
A retrospective cohort study was conducted for the years 2001 through 2010, based on medical claims data from the Deseret Mutual Benefit Administrators (DMBA).
Thirty-four cases of TD and 229 cases of SD were identified. The incidence rate of TD among persons previously prescribed an antipsychotic or metoclopramide (MCP) (per 1,000) was 4.6 (1.6-7.7) for those with antipsychotic drug use only, 8.5 (4.8-12.2) for those with MCP use only, and 15.0 (2.0-28.1) for those with both antipsychotic and MCP use. In the general population, the incidence rate (per 100,000 person-years) of TD was 4.3 and of probable SD was 28.7. The incidence rates of TD and SD increased with age and were greater for females. Those with diabetes or psychoses had almost a 3-fold greater risk of TD than those without either of these diseases. Persons with schizophrenia had 31.2 times increased risk of TD than those without the disease. Positive associations also existed between the selected diseases and the incidence rate of probable SD, with persons with schizophrenia having 4.4 times greater risk of SD than those without the disease.
SD and TD are rare in this general population. Diabetes, psychoses, and especially schizophrenia are positively associated with SD and TD. A higher proportion of those with SD present with spasm of the eyelid muscles (blepharospasm) compared more with the TD cases who present more with orofacial muscular problems.
The introduction of chlorpromazine and other antipsychotic drugs into medical practice in the 1950’s revolutionized the treatment of schizophrenia. However, these drugs were not without some unanticipated side effects. The most common were increased occurrence of neuromuscular problems, especially Parkinson’s like muscle rigidity. A less common side effect was dyskinesia. Dyskinesia manifests its presence as abnormal involuntary, repetitive, persistent, stereotypic movements usually of the facial muscles but can also involve other muscle groups including the extremities and the torso . When this condition occurs sometime after the initiation of antipsychotic drugs that damage GABAergic medium spiny neurons (MSNs), it is referred to as tardive (or delayed) dyskinesia (TD) . New research has distinguished MSNs as the first station in the corticostriato-thalamo-cortical circuit that regulates the amplitude and velocity of movements .
Studies have identified an elevated risk of dyskinesia among schizophrenics exposed to first- and second-generation neuroleptic (antipsychotic) drugs, with second-generation neuroleptics posing a lower risk [3–7]. First-generation antipsychotic drugs are more likely to cause movement disorders because they bind tightly to dopaminergic neuroreceptors (e.g., haloperidol). Nevertheless, some of these earlier developed drugs are still in use today. There is currently little information as to the incidence rate of dyskinesia among those without an underlying psychosis. Other drugs, especially metoclopramide used for the treatment of gastric paresis, were also claimed to increase the incidence of TD. The common pathway for these side effects relates to the dopamine-2 receptors in the brain.
It is now recognized that antipsychotic-naïve individuals can develop involuntary movement disorders and these are classified as spontaneous dyskinesia (SD) [8–10]. Drugs associated with TD are chlorpromazine and other antipsychotic drugs and metoclopramide (MCP) [3, 11, 12]. Spontaneous and tardive dyskinesia are more common in older ages [13, 14]. The incidence of spontaneous dyskinesia by age and sex has not been well studied. For drug-related dyskinesia, the incidence may be related to the increased use of neuroleptic drugs or MCP in older individuals. For example, MCP is used to treat gastrointestinal problems associated with diabetes mellitis. In addition, there is a strong correlation between age and cumulative antipsychotic exposure.
In addition to MCP and antipsychotic drugs, diabetes mellitus has been reported to be a risk factor for TD [15, 16], although there remains some uncertainty about the causal mechanisms of this link . Diabetes may be associated with TD because MCP has been used to treat gastro-paresis, a consequence of severe diabetes [18, 19]. Other studies have suggested an independent association between dyskinesia and diseases such as diabetes, schizophrenia, and other psychoses in the absence of ingestion of MCP or antipsychotic [8–10]. While the focus in this paper is on first-generation antipsychotics and dyskinesia, newer second-generation antipsychotics (e.g., clozapine and olanzapine) have been shown to cause problems related to metabolic syndrome, thereby contributing to obesity and type 2 diabetes mellitus .
Prevalence and incidence rates of TD and SD have varied widely because of differences in patient characteristics and methodological approaches. Most studies have used cross-sectional (or prevalence) data on patients with schizophrenia or other psychoses, but some have used retrospective cohort data and a small number have used prospective cohort data [3, 4, 8–10, 21, 22]. The purpose of the current study was to determine the incidence of all types of dyskinesia in general population and also to examine its connection to underlying medical conditions such as diabetes independent of antipsychotic medication use, and in association with use of first-generation antipsychotic drugs and metoclopramide.
A retrospective cohort study was conducted using data from the Deseret Mutual Benefit Administrators (DMBA), a health insurance company for employees of the Church of Jesus Christ of Latter-day Saints. The company was established in 1970 to provide health insurance and retirement income to church employees and their families. There are about 80,000 individuals covered by the DMBA each year. There is little employee turnover, estimated at less than 5% per year . The majority of turnover occurred among young adults who lose eligibility for coverage under their parents’ health insurance plan and individuals who become eligible for Medicare. Membership in the church is a requirement for employment, with two exceptions; employees of Deseret management companies and commercial enterprises do not need to be members of the church (roughly 11-13% of enrollees). The majority (70%) of enrollees work in Utah. Approximately 45.6% of enrollees are employed in the Latter-day Saint Church education system principally as teachers; 21.1% of enrollees are maintenance and custodial workers; and the remaining 33.3% work in other capacities for the Church. There is a relatively low prevalence of tobacco smoking, alcohol consumption, and illicit drug use among members of the database due to the proscription of these substances by the Latter-day Saint Church .
Employees, spouses and dependent children are included in the database. During the study period 2001 through 2010, there were 144,308 distinct individuals in the database and they accrued 798,542 person-years of observation. Mean age increased from 34.7 (SD = 23.3) in 2001 to 37.1 (SD = 24.6) in 2010, with 49.9% ages 0–24, 20.6% ages 25–44, 19.0% ages 45–64, and 10.5% ages 65 years and older. The percentage of males was slightly lower than females (49.2 vs. 50.8%). At age 65, many move to Medicare, but purchase supplemental insurance through DMBA. The supplemental insurance should capture all new claims for these individuals.
The database was de-identified according to Health Insurance Portability and Accountability Act (HIPAA) guidelines and was exempt from the need for informed consent by the Institutional Review Board at the University of Utah. The current study was approved and classified as a low risk study by the Institutional Review Board.
The primary outcome variables of interest were tardive dyskinesia (TD) and spontaneous dyskinesia or dystonia (SD).
Tardive dyskinesia and SD were identified by any one (or a combination) of the International Classification of Diseases, 9th Revision (ICD-9), codes 333.81, 333.82, 333.83, 333.84, 333.85 (a new code introduced October 1, 2006), and 333.89 being present on a paid DMBA claim as a reason for the enrollee’s office visit . If a claim was filed for use of any antipsychotic drug and/or MCP prior to the claim for dyskinesia, the disease was classified as TD, otherwise as SD. The ICD coding system did not include a separate code for a dyskinesia that appeared after exposure to medication until October 2006 when the code 333.85 was then introduced. For this study we reviewed each individual’s prescription drug use and only included those with prior history of antipsychotic or MCP use before the diagnosis of any type of dyskinesia. We then combined those with prior drug exposure with any of the dyskinesia codes with the new 333.85 code. Among 263 patients with one of the ICD-9 codes for a specific dyskinesia, 34 were classified as TD and 229 as SD.
In this study, we defined a person as having “probable TD” or “probable SD” if he/she had one or more claims involving the above ICD-9 codes (and met the medication use criteria above). We also present results with a stricter definition of TD and SD, wherein at least two claims were paid for the dyskinesia within a 12 month time period. Our reasoning was that a physician may make a tentative diagnosis based on a single visit by a patient with a complaint of unexplained involuntary muscular movements. If symptoms persisted, then this would cause the individual to make a second visit, and so two visits within one year with the same diagnosis would be more likely to identify a patient with actual disease. This definition better fits the Schooler-Kane criteria for the diagnosis of TD or SD that only accepts a diagnosis based on two separate examinations three months apart . The confidentiality agreement that covers our use of the DMBA database does not allow us to characterize physicians by their medical specialty so it was not possible to identify how many diagnoses were made by a primary care physician and how many were made by a neurologist, or psychiatrist.
An antipsychotic is any drug used to treat psychosis, particularly schizophrenia. For the purpose of this study, we restricted our analysis to the classic antipsychotic drugs, which were introduced into psychiatric practice in the 1950’s and were still in use between 2001 and 2010. Classical antipsychotic drugs have a proven or suspected association with TD. Antipsychotic drugs were chosen from lists of classic drugs used during 2001 through 2010 [27, 28]: amitriptyline, chlorpromazine, compazine, etrafon, fluphenazine, haldol, haloperidol, halperon, kenazine, loxapine, loxitane, maxolon, melacen, mellaril, mesoridazine besylate, millazine, moban, navane, orap, ormazine, perphenazine, prochlorperazine, serentil, stalizin, thioridazine, triavil, trifluoperazine, trilafon, trifluoperazine. Use of these drugs was identified using corresponding National Drug Codes (NDCs), and ranged in dose from 1 mg to 200 mg. In a study involving psychiatric patients over 45 years of age, use of antipsychotic drugs greater than 30 days was considered to be associated with higher risk for TD . Antipsychotic drug use had to precede TD in order to be considered a cause of the disease.
Researchers have recommended that MCP should not be used for more than 3 months in order to avoid the risk of TD . More recently the Food and Drug Administration (FDA) has recommended that MCP be used for no longer than 30 days to avoid the risk of TD . Both oral and non-oral MCP products are available in the US, each with a unique drug code. The non-oral MCP products include injections and topical preparations. Drug lists were queried to find the oral and injection products of MCP. The National Drug Code (NDC), and identification number issued by the FDA, is the reference used in the DMBA database. The following national drug current MCP products, as well as products withdrawn during the analysis period, were used in the study: metoclopramide, metoclopramine, metozolv, myclopramide, octamide, raglan. These medications ranged in dose from 5 mg to 10 mg. Topical MCP was not used in assessing MCP exposure because transdermal absorption is low [31, 32].
Diabetics are at increased risk for gastroparesis and MCP has been the preferred drug to treat this condition . Both type I and II diabetes mellitus were included in the study. The ICD-9 code 250 was used to identify a case. Hyperglycemia NOS (ICD-9 codes 790.6), neonatal diabetes mellitus (775.1), nonclinical diabetes (790.2), and diabetes complicating pregnancy, childbirth, or the puerperium (648.0) were excluded. Diabetes was only associated with dyskinesia if it was diagnosed prior to TD or SD.
Individuals with psychoses may be at increased risk of spontaneous movement disorders, even without a history of MCP or antipsychotic drug use [6, 7, 33, 34]. The ICD-9 code 295 was used to identify persons with schizophrenia, and codes 296–299 were used to identify other psychoses: affective psychoses (ICD-9 = 296), paranoid states (ICD-9 = 297), other nonorganic psychoses (ICD-9 = 298), and psychoses with origin specific to childhood (ICD-9 = 299). Schizophrenia and other psychoses were only associated with dyskinesia if they were diagnosed prior to TD or SD.
Counts, percentages, and incidence rates were used to describe the data. The incidence rates reflected new cases in the numerator. A table was constructed to calculate the time under observation of each of the individuals included in this study since there were loses and additions of individuals during the 10 years of the study. Each person’s contribution of observable time was calculated based on year end enrollment data and an overall person-time denominator was obtained. We also calculate person-time for those with diabetes, schizophrenia or other psychoses. This allowed us to estimate incidence rates for each of these conditions. Rate ratios were used to measure the association between dyskinesia and the selected diseases and types of medications used. Ninety-five percent confidence intervals were calculated for the rates and rate ratios. Rate ratios were considered significant if the confidence interval did not overlap 1. Statistical significance was based on the two-sided hypothesis and a P value of 0.05 or less. Analyses were performed using SAS 9.3 (SAS Institute Inc., Carry, NC, 2002–2010).
Counts of dyskinesia according to ICD-9 classification
Tardive dyskinesia – drug related …
Orofacial or subacute dyskinesia
Spontaneous dyskinesia – non-drug related …
Orofacial or subacute dyskinesia
Organic writers’ cramp
Tardive Dyskinesia (TD) by prior use of Antipsychotic and/or Metoclopramide
No. of enrollees prescribed medications
No. with ICD-9 Claim 333.81-333.89 within 3 months of medication use
No. with ICD-9 Claim 333.81-333.89 not within 3 months of medication use
Rate of TD per 1,000 treated with medication
No. with ICD-9 Claim 333.81-333.89 within 3 months of medication usea
No. with ICD-9 Claim 333.81-333.89 not within 3 months of medication use a
Rate of TD per 1,000 treated with medication a
Incidence rates of Tardive Dyskinesia and Spontaneous Dykinesia
Rate per 100,000 person-years
Rate per 100,000 person-yearsa
95% CI a
Rate ratio of Tardive Dyskinesia (TD) Spontaneous Dyskinesia (SD) according to diabetes, Schizophrenia, and other Psychoses
We believe this is the first report of the incidence of spontaneous and tardive dyskinesia in a general population. The strengths of the study include a stable population, a ten year period of observation, an accurate measurement of the population at risk, the ability to identify prior diseases from the same database, the ability to link to pharmacy records, stable and experienced physician providers, and a low percentage of tobacco smokers.
Others have made estimates of the incidence of TD. Wiholm and colleagues identified 11 new cases of TD (1 in 2000–2800 treatment-years) in the Swedish population over a five year time period and linked these to use of MCP using reports from an adverse drug reaction reporting system that relied on self-reports by physicians . Their study did not provide information about the incidence of SD, but the authors suggested there was an association between long term use of MCP and the development of TD, because many of those with TD had long term use of MCP. Bateman and colleagues reported the incidence of dystonia and dyskinesia to be 28.6 per million prescriptions of MCP in the United Kingdom, also based on an adverse drug reaction reporting system . The incidence of dystonia and dyskinesia was 1.8 times greater in females than males.
Glazer and colleagues estimated the incidence of TD among a group of patients with schizophrenia confined to a large residential psychiatric hospital after five years of antipsychotic exposure (32%), 15 years of exposure (57%), and 25 years of exposure (68%) . The study did not report information about dyskinesia among those without schizophrenia, nor was information available about dyskinesia among those not exposed to antipsychotic drugs. Inada and colleagues calculated an annual incidence rate of TD among psychiatric patients from 11 facilities in Japan . The study found an annual incidence rate of TD to be 3.7%. Dyskinesia was not reported according to antipsychotic status. None of these studies were controlled for tobacco smoking, which has been suggested to be an independent cause of dyskinesia [37, 38].
These studies are not directly comparable with our study because they tended to focus on individuals continuously exposed to MCP or high doses of antipsychotic drugs among individuals with schizophrenia. Very few in our study likely had long-term exposure to these medications. In addition, their populations involved psychiatric patients severe enough to require long-term institutionalization, whereas none of those with schizophrenia in our population had disease severe enough to be institutionalized. Finally, our population likely had far fewer smokers because tobacco smoking and alcohol drinking are proscribed by the Latter-day Saint Church .
Most other studies have measured the prevalence, not the incidence, of TD. The initial studies measured the prevalence of TD among those committed to psychiatric hospitals for schizophrenia or among patients in extended care facilities with various psychoses . A study by Ganzini and colleagues in 1993 was the first to estimate the prevalence of TD among non-psychiatric outpatients treated for three months or longer with MCP and who received their medical care through a Veterans hospital . The high prevalence of TD among those exposed to MCP compared with the control group (29% versus 16%) led the authors to suggest that TD and SD were common conditions in the general population, and that both drug-induced and spontaneous dystonias were much more serious medical problem than had previously been recognized. A study by Sewell and colleagues, who based their study of TD on veterans receiving medical care at the San Diego VA Medical Center, came to a similar conclusion .
Our study findings differ from those reported in these two earlier papers. Specifically, the incidence rates presented in the current study do not support prevalence rates of 12% to 29% for SD or TD in the general population. A crude estimation of our period prevalence rates based on about 80,000 individuals under observation during each of the 10 years of the study, and cumulating all our cases with two or more visits yields a 10 year period prevalence of 1.8 per 1,000 individuals. For all those using the antipsychotic drugs and MCP, we have a prevalence of 6.1 per 1000. The crude estimate of period prevalence will be higher than the actual estimate of point prevalence since it does not allow for individuals with dyskinesia to leave the population during the study period. Closer to our results, Inada and colleagues found a prevalence of TD of 8%, based on psychiatric patients from 11-facilities in Japan .
The reason for such a large discrepancy between these rates is not readily apparent. Both the studies used a more precise diagnostic measure for dyskinesia, but only applied it once, thus including individuals who did not meet the Schooler-Kane criteria. In the study by Ganzini and colleagues, 19% of the control group also was reported to have undiagnosed Parkinson’s disease . Selection bias is a likely explanation for the disparity in the results and was not considered by the authors of these studies. Specifically, overestimation of the true association between antipsychotic drug use or MCP and dyskinesia will be greater in studies involving psychiatric patients than for the general population because the association will be evaluated more rigorously in the patient population.
Our findings provide evidence for an independent association between TD and each of the health conditions (diabetes mellitus, psychoses, and especially schizophrenia). This is consistent with previous studies examining the association between these health conditions and TD [15, 16], as well as with SD where antipsychotic drugs were not used [8–10]. The greater than 30-fold increased risk of TD among those with schizophrenia (and exposure to an antipsychotic drug) compared with those without schizophrenia is congruent with what many others have reported previously. The estimate is much higher than that reported by Morgenstern and colleagues . We do not have an explanation for this difference. Our findings also provide evidence for an independent association between each of the selected health conditions and SD. The finding of a 4-fold increased risk of spontaneous dyskinesia among persons with schizophrenia (but no exposure to an antipsychotic drug) compared with those without schizophrenia may be a result of the underlying disease, as suggested by others [8–10].
Our study reports data from a defined population, all with health insurance, and coverage for prescription medication. We ascertained the incidence of the SD and TD using this system. There were no changes in the medical coverage of this population during the 10 years of the study that could bias our findings. Our definition of a new case of SD or TD meets minimal standards for such a diagnosis, two episodes separated by up to a year. Because of the nature of the data base individual cases could not be confirmed by an independent examination. The most likely outcome of an independent examination using more precise diagnostic criteria such as the Abornormal Involuntary Movement Scale (AIMS) would be to eliminate some of the individuals who we classified as having SD or TD, and lower the incidence rates. For this reason we consider the incidence rates we report to likely overestimate the true incidence of SD or TD in any general population.
Although the results of this study are important, they should be interpreted with some caution. The study is limited in that the information was obtained purely from an insurance database, and not by clinical evaluations. Examination for and documentation of dyskinesia may have been influenced by the fact that the subject was taking antipsychotic drugs. However, selection bias is likely to be much smaller in our study involving the general population than in a select group of psychiatric patients, especially if they were known to have long-term exposure to antipsychotic drugs or MCP. In addition, the nature and distribution of the movement disorder may not have been accurately documented unless the subject was examined by a neurologist, or ideally, a movement disorders specialist. Finally, the data began in 2001 such that we were unable to determine the duration of medication use. Analyses were based on any prior antipsychotic or MCP medication use, as recorded in the database.
The incidence of spontaneous and tardive dyskinesia is rare in a large, generally non-smoking population. We were able to confirm estimates by others that diabetes mellitis is associated with increased risk of spontaneous dyskinesia. A higher proportion of those with spontaneous dyskinesia present with spasm of the eyelid muscles (blepharospasm) compared to those with tardive dyskinesia who present with orofacial muscular problems.
- Stedman JK: Stedman’s medical dictionary for the health professions and nursing. 2005, Baltimore, MD: Lippincott Williams & WilkinsGoogle Scholar
- Loonen AJ, Ivanova SA: New insights into the mechanism of drug-induced dyskinesia. CNS Spectr. 2013, 18 (1): 15-20. 10.1017/S1092852912000752.View ArticlePubMedGoogle Scholar
- Glazer GM: Review of incidence studies of tardive dyskinesia associated with typical antipsychotics. J Clin Psychiatry. 2000, 61 (4): 15-20.PubMedGoogle Scholar
- Morganstern M, Glazer WM, Niedzwiecki D, Nouriah P: The impact of neuroleptic medication on tardive dyskinesia: a meta-analysis of published studies. AJPH. 1987, 77 (6): 717-724. 10.2105/AJPH.77.6.717.View ArticleGoogle Scholar
- Tenback DE, van Harten PN, Slooff CJ, Belger MA, van Os J, SOHO Study Group: Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study. J Clin Psychiatry. 2005, 66 (9): 1130-1133. 10.4088/JCP.v66n0907.View ArticlePubMedGoogle Scholar
- Correll CU, Schenk EM: Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry. 2008, 21 (2): 151-156. 10.1097/YCO.0b013e3282f53132.View ArticlePubMedGoogle Scholar
- Keltner NL, Folks DG: Psychotropic Drugs. 2005, Maryland Heights, MO: Elsevier Mosby, 4Google Scholar
- Gervin M, Browne S, Lane A, Clarke M, Waddington JL, Larkin C, O’Callaghan E: Spontaneous abnormal involuntary movements in first-episode schizophrenia and schizophreniform disorder: baseline rate in a group of patients from an Irish catchment area. Am J Psychiatry. 1998, 155 (9): 1202-1206.View ArticlePubMedGoogle Scholar
- McCreadie RG, Padmavati R, Thara R, Srinivasan TN: Spontaneous dyskinesia and parkinsonism in never-medicated, chronically ill patients with schizophrenia: 18-month follow-up. Br J Psychiatry. 2002, 181: 135-137.View ArticlePubMedGoogle Scholar
- Fenton WS, Wyatt RJ, McGlashan TH: Risk factors for spontaneous dyskinesia in schizophrenia. Arch Gen Psychiatry. 1994, 51 (8): 643-650. 10.1001/archpsyc.1994.03950080055008.View ArticlePubMedGoogle Scholar
- Wiholm BE, Mortimer Ö, Boethius G, Häggström JE: Tardive dyskinesia associated with Metoclopramide. BMJ. 1984, 288 (6416): 545-547. 10.1136/bmj.288.6416.545.View ArticlePubMedPubMed CentralGoogle Scholar
- Ganzini L, Casey DE, Hoffman WF, McCall AL: The prevalence of metoclopramide-induced Tardive Dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med. 1993, 153: 1469-1475. 10.1001/archinte.1993.00410120051007.View ArticlePubMedGoogle Scholar
- Smith JM, Baldessarini RJ: Changes in prevalence, severity and recovery in tardive diskinesia with age. Arch Gen Psychiatry. 1980, 37: 1368-1373. 10.1001/archpsyc.1980.01780250054006.View ArticlePubMedGoogle Scholar
- Inada T, Ohnishi K, Kamisada M, Matsuga G, Tajima O, Hashiguchi K, Shima S, Oh-e Y, Masuda Y: A prospective study of tardive diskinesia in Japan. Eur Arch Psychiatry Clin Neurosci. 1991, 240 (4–5): 250-254.View ArticlePubMedGoogle Scholar
- Woerner MG, Saltz BL, Kane JM, Lieberman JA, Alvir JMJ: Diabetes and development of tardive diskinesia. Am J Psychiatry. 1993, 150: 966-968.View ArticlePubMedGoogle Scholar
- Ganzini L, Heintz RT, Hoffman WF, Casey DE: The prevalence of tardive dyskinesia in neuroleptic-treated diabetics. A controlled study. Arch Gen Psychiatry. 1991, 48 (3): 259-263. 10.1001/archpsyc.1991.01810270071010.View ArticlePubMedGoogle Scholar
- Raja M, Azzoni A: Diabetes is not a risk factor for tardive dyskinesia. A retrospective observational study. Hum Psychopharmacol Clin Exp. 2001, 17: 61-63.View ArticleGoogle Scholar
- Pasricha JP, Pelivanov N, Sugumar A, Jankovic J: Drug insight: from disturbed motility to disordered movement- a review of the clinical benefits and medicological risks of metoclopramide. Nature. 2006, 3 (3): 138-148.Google Scholar
- Tang DM, Friedenberg FK: Gastroparesis: approach, diagnostic evaluation, and management. Dis Mon. 2011, 57 (2): 74-101. 10.1016/j.disamonth.2010.12.007.View ArticlePubMedGoogle Scholar
- Muench J, Hamer AM: Adverse effects of antipsychotic medications. Am Fam Physician. 2010, 81 (5): 617-622.PubMedGoogle Scholar
- Sweet RA, Mulsant BH, Rifai AH, Zubenko GS: Dyskinesia and neuroleptic exposure in elderly psychiatric inpatients. J Geriatr Psychiatry Neurol. 1992, 5 (3): 156-161.View ArticlePubMedGoogle Scholar
- Yassa R, Nastase C, Dupont D, Thibeau M: Tardive dyskinesia in elderly psychiatric patients: a 5-year study. Am J Psychiatry. 1992, 149 (9): 1206-1211.View ArticlePubMedGoogle Scholar
- Merrill RM, Lyon JL, Baker RK, Gren LH: Attention deficit hyperactivity disorder and increased risk of injury. Adv Med Sci. 2009, 54 (1): 20-26.View ArticlePubMedGoogle Scholar
- Merrill RM, Lindsay GB, Lyon JL: Tobacco-related cancers in the Utah compared to the United States: Quantifying the benefits of the Word of Wisdom. BYU Studies. 1999, 38 (4): 91-105.Google Scholar
- ICD-9-CM: International Classification of Diseases, 9th Revision; Clinical Modification. 2006, Los Angeles, CA: PMIC, 7Google Scholar
- Schooler NR, Kane JM: Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry. 1982, 39: 486-PubMedGoogle Scholar
- Stringer J: Basic Concepts in Pharmacology: What You Need to Know for Each Drug Class. 2011, New York, NY: McGraw-Hill Companies Inc., 4Google Scholar
- Alan FS, Nemeroff CB: The American Psychiatric Publishing Textbook of Psychopharmacology. 2009, Arlington, VA: American Psychiatric Publishing, 4Google Scholar
- Jeste DV, Lacro JP, Palmer B, Rockwell E, Harris MJ, Caligiuri MP: Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients. Am J Psychiatry. 1999, 156 (2): 309-311.PubMedGoogle Scholar
- FDA News Release: FDA requires boxed warning and risk mitigation strategy for Metoclopramide containing drugs: Agency warns against chronic use of these products to treat gastrointestinal disorders. 2009, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm149533.htm,Google Scholar
- Blanes C, Colom H, Moreno J, Obach R, Peraire C, Domenech J: Comparative study “in vitro” of transdermal absorption of a series of antiemetic drugs. Eur J Drug Metab Pharmacokinet. 1991, 3: 410-414.Google Scholar
- Calpena AC, Blanes C, Moreno J, Obach R, Domenech J: A comparative in vitro study of transdermal absorption of antiemetics. J Pharm Sci. 1994, 83 (1): 29-33. 10.1002/jps.2600830108.View ArticlePubMedGoogle Scholar
- Pappa S, Dazzan P: Spontaneous movement disorders in antipsychotic-naive patients with first-episode psychoses: a systematic review. Psychol Med. 2009, 39: 1065-1076. 10.1017/S0033291708004716.View ArticlePubMedGoogle Scholar
- Lee J, Poon L, Chong S: Spontaneous dyskinesia in first-episode psychosis in a Southeast Asian population. J Clin Psychopharmacol. 2008, 28: 536-539. 10.1097/JCP.0b013e3181845f59.View ArticlePubMedGoogle Scholar
- Bateman DN, Rawlins MD, Simpson JN: Extrapyramidal reactions with metoclopramide. Brit Med J. 1985, 291: 930-932. 10.1136/bmj.291.6500.930.View ArticleGoogle Scholar
- Glazer WM, Morgenstern H, Doucette JT: Predicting long term risk of tardive dyskinesia in outpatients maintained on neuroleptic medication. J Clin Psychiatry. 1993, 54: 133-139.PubMedGoogle Scholar
- Nilsson A, Waller L, Rosengren A, Adlerberth A, Wilhelmsen L: Cigarette smoking is associated with abnormal involuntary movements in the general male population–a study of men born in 1933. Biol Psychiatry. 1997, 41 (6): 717-723. 10.1016/S0006-3223(96)00289-2.View ArticlePubMedGoogle Scholar
- Chong SA, Tan EC, Tan CH: Smoking and tardive dyskinesia: lack of involvement of the CYP1A2 gene. J Psychiatry Neurosci. 2003, 28 (3): 185-189.PubMedPubMed CentralGoogle Scholar
- Sewell DD, Kodsi AB, Caligiuri MP, Jeste DV: Metoclopramide and tardive dyskinesia. Biol Psychiatry. 1994, 36: 630-632. 10.1016/0006-3223(94)90077-9.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-244X/13/152/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.